How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Diagnostic assay for recent flavivirus infections: Zika, Dengue, Tick-borne encephalitis

Organization name

Medical University of Vienna

Profile

The assay detects IgM antibodies with high sensitivity and specificity and thus provides a means for the early serological diagnosis of flavivirus infections. It is based on an IgM-capture format and highly purifiedre combinant viral antigens, allowing the differentiation between infections with antigenically closely related flaviviruses like dengue and Zika viruses.The IgM-capture format is robust, can be easily standardized and readily adapted to existing diagnostic systems for antibody detection.

Background

Flavivirus infections occur worldwide; e.g. dengue and Zika in tropical and subtropical regions, tick-borne encephalitis in large parts of Europe and Asia. The overlap of endemic regions and the similarity of symptoms underscore the importance of laboratory diagnostic differentiation between dengue and Zika virus infections. Since the time window for direct virus detection by PCR is limited, lying often before the occurrence of symptoms, IgM antibody detection is an essential tool for the diagnosis of recent flavivirus infections. Such assays are thus required in endemic regions as well as globally for verifying flavivirus infections in travelers.

Technology

The diagnostic assay is based on an IgM-capture format and highly purified recombinant viral antigens. It detects antibodies from patient samples and differentiates between infections with antigenically closely related flaviviruses like dengue and Zika viruses or the 4 dengue serotypes.

Benefits

  • High specificity and sensitivity
  • Differentiation between dengue and Zika virus infections
  • Pure components facilitate production and standardization
  • Readily adaptable to existing assay systems
  • Global market
  • Easy to use for diagnostic laboratories

Available for

  • License agreement
  • Development partnership

Development Status

Assay established in research and routine diagnostic lab

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries